



(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 54

(51) Int Cl.:
A61N 1/08 (2006.01) **A61N 1/05 (2006.01)**
A61N 1/32 (2006.01) **A61B 18/14 (2006.01)**

(48) Corrigendum issued on:
03.04.2013 Bulletin 2013/14

(43) Date of publication:
27.02.2013 Bulletin 2013/09

(21) Application number: **12180426.4**

(22) Date of filing: **05.10.2005**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **13.05.2005 US 129765**
05.10.2004 US 616254 P
02.11.2004 US 624793 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
11192511.1 / 2 457 614
10190952.1 / 2 329 859
05806045.0 / 1 802 370

(71) Applicant: **Medtronic Ardian Luxembourg S.à.r.l.**
2124 Luxembourg (LU)

(72) Inventors:
• **Deem, Mark**
Mountain View, CA California (US)
• **Gifford, Hanson**
Woodside, CA California (US)

- **Zarins, Denise**
Saratoga, CA California 95070 (US)
- **Sutton, Douglas**
Pacifica, CA California (US)
- **Thai, Erik**
San Jose, CA California (US)
- **Gelfand, Mark**
New York, NY New York 10001 (US)
- **Levin, Howard R.**
Teaneck, NJ New Jersey 07666 (US)

(74) Representative: **Zimmermann & Partner**
Josephspitalstr. 15
80331 München (DE)

Remarks:

- This application was filed on 14-08-2012 as a divisional application to the application mentioned under INID code 62.
- Claims filed after the date of filing of the application / after the date of receipt of the divisional application (Rule 68(4) EPC).

(54) **Apparatus for renal neuromodulation**

(57) Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.




FIGURE 4